Recruiting
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
This is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collected data will be utilized to develop an ILC specific response assessment tool.
ClinicalTrials.gov IDNCT05964504
PhaseNot Applicable
Enrollment150
SponsorUniversity of California, San Francisco
Age18 Years and older
SexALL
Conditions studied
Metastatic Breast Cancer, Lobular Breast Carcinoma
About this study
This is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collected data will be utilized to develop an ILC specific response assessment tool.
Interventions
- Procedure: Blood Specimen — Blood will be drawn via venipuncture
Primary outcomes
- Feasibility of registry (Up to 2 years)
- Proportion of patients with measurable versus unmeasurable disease (Up to 10 years)
- Median Progression Free Survival Rate (Up to 10 years)
- Median Overall Survival Rates (Up to 10 years)
Eligibility information
Inclusion Criteria:
1. Histologically confirmed invasive lobular carcinoma. Mixed lobular/ductal cancer is allowed.
2. Age \>=18 years
3. Any receptor subtype.
4. Ability to understand a written informed consent document, and the willingness to sign it.
Exclusion Criteria:
1. Stage I-III breast cancer.
2. Lack of lobular histology on tumor biopsy.
3. Other active cancer (prior treated cancer with no current evidence of disease is allowed).
Study locations
- University of California, San Diego, San Diego, California 92053 United States
- University of California, San Francisco, San Francisco, California 94122 United States
- Abramson Cancer Center, Philadelphia, Pennsylvania 19104 United States
- MD Anderson Cancer Center, Houston, Texas 77030 United States
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-10-28.